Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26572007 | 0.85 | EPHX1 (0.36) | TSHRRAB9ACYP3A4LMNANFKB1 | |
| SCHEMBL20848107 | 0.82 | CNR2 (0.33) | POLBTSHRRAB9ANPC1 | |
| SCHEMBL17814864 | 0.82 | RAB9A (0.35) | TSHRRAB9ALMNANFKB1NPC1 | |
| SCHEMBL19049882 | 0.82 | RAB9A (0.35) | TSHRRAB9ALMNANFKB1NPC1 | |
| SCHEMBL21126501 | 0.82 | RAB9A (0.35) | TSHRRAB9ALMNANFKB1NPC1 | |
| SCHEMBL20352484 | 0.82 | RAB9A (0.35) | TSHRRAB9ALMNANFKB1NPC1 | |
| SCHEMBL26801217 | 0.82 | RAB9A (0.35) | TSHRRAB9ALMNANFKB1NPC1 | |
| SCHEMBL23962141 | 0.82 | RAB9A (0.33) | RAB9ANPC1CYP19A1 | |
| SCHEMBL23453068 | 0.81 | TSHR (0.33) | TSHRRAB9ACYP3A4LMNANFKB1 | |
| SCHEMBL25002316 | 0.81 | TSHR (0.33) | TSHRRAB9ACYP3A4LMNANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634448-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634448-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | POLB 4356/4885TSHR 3743/4885RAB9A 4435/4885 |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | POLB 4356/4885TSHR 3743/4885RAB9A 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.